Lamisil Poses Serious Health Risks: Report

Law360, New York (February 13, 2008, 12:00 AM EST) -- Novartis AG's oral fungal infection treatment Lamisil appears to put patients at risk of serious, and even life-threatening, liver, blood and skin problems, an Australian health regulator has reported.

The Australian Adverse Drug Reactions Advisory Committee said earlier this month that it had received 722 reports of harmful side effects from terbinafine, an oral version of the cream used to treat skin and nail fungal infections, sold under the brand name Lamisil. Three of those patients died from liver failure.

ÔÇťADRAC reminds prescribers that oral terbinafine...
To view the full article, register now.

UK Financial Services

UK Financial Services

Read Our Latest UK Financial Services Coverage

Financial Services Law360 UK provides breaking news and analysis on the financial sector. Coverage includes UK and European Union policy, enforcement, and litigation involving banks, asset management firms, and other financial services organizations.